{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:15:31Z","timestamp":1791778531154,"version":"4.3.4"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,3,31]],"date-time":"2008-03-31T00:00:00Z","timestamp":1206921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Clin Pharmacol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1186\/1472-6904-8-2","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T06:14:18Z","timestamp":1207030458000},"source":"Crossref","is-referenced-by-count":9,"title":["Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study"],"prefix":"10.1186","volume":"8","author":[{"given":"Andrew","family":"Spencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nola","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ravera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Cremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanela","family":"Bilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Neeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Copeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Schran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,31]]},"reference":[{"issue":"2","key":"52_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.1365-2141.2002.03835_4.x","volume":"119","author":"SG Jones","year":"2002","unstructured":"Jones SG, Dolan G, Lengyel K, Myers B: Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol. 2002, 119 (2): 576-7. 10.1046\/j.1365-2141.2002.03835_4.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"52_CR2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0731-7085(02)00218-2","volume":"30","author":"F Legay","year":"2002","unstructured":"Legay F, Gauron S, Deckert F, Gosset G, Pfaar U, Ravera C, Wiegand H, Schran H: Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. J Pharm Biomed Anal. 2002, 30 (4): 897-911. 10.1016\/S0731-7085(02)00218-2.","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"52_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1177\/009127002762491316","volume":"42","author":"T Chen","year":"2002","unstructured":"Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002, 42 (11): 1228-36. 10.1177\/009127002762491316.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"52_CR4","first-page":"478","volume":"7","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A: A Phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001, 7 (3): 478-85.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-8-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6904-8-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-8-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T05:42:28Z","timestamp":1468647748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1186\/1472-6904-8-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,31]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1186\/1472-6904-8-2","relation":{},"ISSN":["1472-6904"],"issn-type":[{"value":"1472-6904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,31]]},"article-number":"9000"}}